Review Process

At Prostate Cancer Canada, we know that we have been entrusted with a very special mission – to allocate the funds raised by Canadians to programs that support research that will have the greatest potential to improve prostate cancer prevention, diagnosis and treatment and to better manage survivorship. To that end, we employ an equitable, transparent selection process that is free from bias to determine which proposals are funded.

We want to be strategic to ensure we are investing in the absolute best prostate cancer research conducted in this country that is also globally competitive.To do this, we engage leading experts in prostate cancer research to help develop the most effective research programs to allow our outstanding research community to achieve research success.

To ensure that Prostate Cancer Canada funds the best ideas, regardless of the area of specialization or where the research is conducted, each research proposal undergoes a rigorous peer-review process. In this way, high-quality, unbiased reviews by experts determine which research is funded.

Prostate Cancer Canada’s review process applies scientific rigor to decision-making related to research while ensuring the process is lean and efficient. Applicants receive feedback from the review process to help them to best assess their strengths and weaknesses to allow for continued improvement in future applications.  Furthermore,  PCC takes conflicts of interest between the review panel and applicants very seriously and has enacted measures to address such occurrences.

Review panels comprise prostate cancer researchers from across Canada who collectively represent all areas of the spectrum of prostate cancer research, including biomedical, translational and population health divisions. Additionally, representatives from the non-scientific, patient or survivor community are invited to serve on the review panel and fulfil a crucial role in giving the non-scientific community a voice at the table.


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
New test developed to detect men at high risk of prostate cancer recurrence

Vienna, Austria: A new genetic “signature” to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). More

CanCertainty for All: Cancer’s Not Fair, But Accessing Treatment Should Be

Toronto, ON – March 10, 2014 – There is no disputing a cancer diagnosis is among the worst news a person or their family could receive. More

$1.8 Million awarded to Movember Rising Stars Supporting Innovators in Prostate Cancer Research

Toronto, ON – February 12, 2014 – Prostate Cancer Canada (PCC) is proud to announce the recipients of its 2014 Movember Rising Star awards in prostate cancer research. More

Support for Those Affected by Prostate Cancer

Toronto, ON - January 28, 2014 – We are pleased to announce a partnership between Prostate Cancer Canada and the Canadian Cancer Society in launching the Prostate Cancer Information Service (PCIS), which provides support to anyone affected by prostate cancer. More


Click here for news archive